NCT07927998
A Study of Retifanlimab After Chemoradiation in People With Anal Cancer
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Rate of ctDNA clearance at 12 weeks
Timeframe: 12 weeks
Arms and interventions
Anal squamous cell carcinomaExperimental
Participants have pathologically confirmed anal squamous cell carcinoma
Drugs: Retifanlimab
Sites
7 sites in 1 country